ITRM20020253A1 - Molecole chimeriche di snrna con sequenze antisenso per le giunzioni di splicing del gene della distrofina e applicazioni terapeutiche. - Google Patents

Molecole chimeriche di snrna con sequenze antisenso per le giunzioni di splicing del gene della distrofina e applicazioni terapeutiche.

Info

Publication number
ITRM20020253A1
ITRM20020253A1 IT2002RM000253A ITRM20020253A ITRM20020253A1 IT RM20020253 A1 ITRM20020253 A1 IT RM20020253A1 IT 2002RM000253 A IT2002RM000253 A IT 2002RM000253A IT RM20020253 A ITRM20020253 A IT RM20020253A IT RM20020253 A1 ITRM20020253 A1 IT RM20020253A1
Authority
IT
Italy
Prior art keywords
gene
snrna
dystrophine
therapeutic applications
antisense sequences
Prior art date
Application number
IT2002RM000253A
Other languages
English (en)
Inventor
Irene Bozzoni
Angelis Fernanda Gabriella De
Original Assignee
Univ Roma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Roma filed Critical Univ Roma
Priority to IT2002RM000253A priority Critical patent/ITRM20020253A1/it
Publication of ITRM20020253A0 publication Critical patent/ITRM20020253A0/it
Priority to EP03749984A priority patent/EP1501931B1/en
Priority to PCT/IT2003/000273 priority patent/WO2003095647A2/en
Priority to DE60330136T priority patent/DE60330136D1/de
Priority to EP09176221.1A priority patent/EP2151497B1/en
Priority to AU2003231928A priority patent/AU2003231928A1/en
Priority to AT03749984T priority patent/ATE449170T1/de
Priority to SI200331749T priority patent/SI1501931T1/sl
Priority to DK03749984.5T priority patent/DK1501931T3/da
Priority to PT03749984T priority patent/PT1501931E/pt
Priority to ES03749984T priority patent/ES2336909T3/es
Publication of ITRM20020253A1 publication Critical patent/ITRM20020253A1/it
Priority to CY20101100102T priority patent/CY1109746T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IT2002RM000253A 2002-05-08 2002-05-08 Molecole chimeriche di snrna con sequenze antisenso per le giunzioni di splicing del gene della distrofina e applicazioni terapeutiche. ITRM20020253A1 (it)

Priority Applications (12)

Application Number Priority Date Filing Date Title
IT2002RM000253A ITRM20020253A1 (it) 2002-05-08 2002-05-08 Molecole chimeriche di snrna con sequenze antisenso per le giunzioni di splicing del gene della distrofina e applicazioni terapeutiche.
ES03749984T ES2336909T3 (es) 2002-05-08 2003-05-06 Molaculas de arnsn quimericas que transportan secuencias antisentido contra las uniones por corte y empalme del gen de la distrofina y sus aplicaciones terapeuticas.
EP09176221.1A EP2151497B1 (en) 2002-05-08 2003-05-06 Chimeric U1 and U2 snRNA molecules carrying antisense sequences against the splice junctions of the dystrophin gene and their therapeutic applications
PCT/IT2003/000273 WO2003095647A2 (en) 2002-05-08 2003-05-06 CHIMERIC snRNA MOLECULES CARRYING ANTISENSE SEQUENCES AGAINST THE SPLICE JUNCTIONS OF THE DYSTROPHIN GENE AND THEIR THERAPEUTIC APPLICATIONS
DE60330136T DE60330136D1 (de) 2002-05-08 2003-05-06 Chimäre snrna moleküle mit antisense-sequenzen gegen die "splice junctions" des dystrophin-gens und ihre therapeutischen verwendungen
EP03749984A EP1501931B1 (en) 2002-05-08 2003-05-06 Chimeric snrna molecules carrying antisense sequences against the splice junctions of the dystrophin gene and their therapeutic applications
AU2003231928A AU2003231928A1 (en) 2002-05-08 2003-05-06 CHIMERIC snRNA MOLECULES CARRYING ANTISENSE SEQUENCES AGAINST THE SPLICE JUNCTIONS OF THE DYSTROPHIN GENE AND THEIR THERAPEUTIC APPLICATIONS
AT03749984T ATE449170T1 (de) 2002-05-08 2003-05-06 CHIMÄRE SNRNA MOLEKÜLE MIT ANTISENSE-SEQUENZEN GEGEN DIE ßSPLICE JUNCTIONSß DES DYSTROPHIN-GENS UND IHRE THERAPEUTISCHEN VERWENDUNGEN
SI200331749T SI1501931T1 (sl) 2002-05-08 2003-05-06 Himerne molekule snrna ki nosijo protismiselne sekvence proti mestu cepitve distrofinskega gena innjihove terapevtske aplikacije
DK03749984.5T DK1501931T3 (da) 2002-05-08 2003-05-06 Kimære snRNA-molekyler, som bærer antisense-sekvenser mod splejsningsforbindelserne af dystrophingenet, og deres terapeutiske anvendelser
PT03749984T PT1501931E (pt) 2002-05-08 2003-05-06 Moléculas de arnnp (snrna) quiméricas portadoras de sequências anti-sentido contra as junções de splicing do gene da distrofina e suas aplicações terapêuticas
CY20101100102T CY1109746T1 (el) 2002-05-08 2010-02-03 Χιμαιρικα μορια snrna που φερουν αντιπληροφοριακες αλληλουχιες εναντι των συνδεσμων συρραφης του γονιδιου δυστροφινης και θεραπευτικες εφαρμογες αυτων

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT2002RM000253A ITRM20020253A1 (it) 2002-05-08 2002-05-08 Molecole chimeriche di snrna con sequenze antisenso per le giunzioni di splicing del gene della distrofina e applicazioni terapeutiche.

Publications (2)

Publication Number Publication Date
ITRM20020253A0 ITRM20020253A0 (it) 2002-05-08
ITRM20020253A1 true ITRM20020253A1 (it) 2003-11-10

Family

ID=11456291

Family Applications (1)

Application Number Title Priority Date Filing Date
IT2002RM000253A ITRM20020253A1 (it) 2002-05-08 2002-05-08 Molecole chimeriche di snrna con sequenze antisenso per le giunzioni di splicing del gene della distrofina e applicazioni terapeutiche.

Country Status (11)

Country Link
EP (2) EP2151497B1 (it)
AT (1) ATE449170T1 (it)
AU (1) AU2003231928A1 (it)
CY (1) CY1109746T1 (it)
DE (1) DE60330136D1 (it)
DK (1) DK1501931T3 (it)
ES (1) ES2336909T3 (it)
IT (1) ITRM20020253A1 (it)
PT (1) PT1501931E (it)
SI (1) SI1501931T1 (it)
WO (1) WO2003095647A2 (it)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999049029A1 (en) 1998-03-20 1999-09-30 Benitec Australia Ltd Control of gene expression
AUPP249298A0 (en) 1998-03-20 1998-04-23 Ag-Gene Australia Limited Synthetic genes and genetic constructs comprising same I
US6423885B1 (en) 1999-08-13 2002-07-23 Commonwealth Scientific And Industrial Research Organization (Csiro) Methods for obtaining modified phenotypes in plant cells
AUPR621501A0 (en) 2001-07-06 2001-08-02 Commonwealth Scientific And Industrial Research Organisation Delivery of ds rna
WO2005026356A1 (en) * 2003-09-12 2005-03-24 Commonwealth Scientific And Industrial Research Organisation Modified gene-silencing nucleic acid molecules and uses thereof
FR2874384B1 (fr) 2004-08-17 2010-07-30 Genethon Vecteur viral adeno-associe pour realiser du saut d'exons dans un gene codant une proteine a domaines dispensables
WO2007123391A1 (en) 2006-04-20 2007-11-01 Academisch Ziekenhuis Leiden Therapeutic intervention in a genetic disease in an individual by modifying expression of an aberrantly expressed gene.
EP1857548A1 (en) 2006-05-19 2007-11-21 Academisch Ziekenhuis Leiden Means and method for inducing exon-skipping
AU2007282224B2 (en) 2006-08-11 2013-08-29 Vico Therapeutics B.V. Methods and means for treating DNA repeat instability associated genetic disorders
EP2152873A2 (en) * 2007-03-16 2010-02-17 Biorigen S.r.l Gene expression regulation technology and noncoding rnas for diagnosis and therapy
US8343941B2 (en) 2007-03-30 2013-01-01 Rutgers, The State University Of New Jersey Compositions and methods for gene silencing
US8907075B2 (en) 2007-03-30 2014-12-09 Samuel Ian Gunderson Compositions and methods for gene silencing
EP2142672B1 (en) * 2007-03-30 2012-09-05 Rutgers, The State University of New Jersey Compositions and methods for gene silencing
US9441221B2 (en) 2007-03-30 2016-09-13 Rutgers, The State University Of New Jersey Compositions and methods for gene silencing
WO2009008727A2 (en) 2007-07-12 2009-01-15 Prosensa Technologies B.V. Molecules for targeting compounds to various selected organs or tissues
CA2693742A1 (en) 2007-07-12 2009-01-15 Prosensa Technologies B.V. Molecules for targeting compounds to various selected organs, tissues or tumor cells
USRE48468E1 (en) 2007-10-26 2021-03-16 Biomarin Technologies B.V. Means and methods for counteracting muscle disorders
AU2008317566B2 (en) 2007-10-26 2014-05-01 Academisch Ziekenhuis Leiden Means and methods for counteracting muscle disorders
NZ587178A (en) 2008-02-08 2011-11-25 Prosensa Holding Bv Methods and means for treating dna repeat instability associated genetic disorders
EP2119783A1 (en) 2008-05-14 2009-11-18 Prosensa Technologies B.V. Method for efficient exon (44) skipping in Duchenne Muscular Dystrophy and associated means
EP2396343B1 (en) 2009-02-11 2017-05-17 The University of North Carolina At Chapel Hill Modified virus vectors and methods of making and using the same
CA2759899A1 (en) 2009-04-24 2010-10-28 Prosensa Technologies B.V. Oligonucleotide comprising an inosine for treating dmd
EP2258863A1 (en) * 2009-05-25 2010-12-08 Universita'Degli Studi di Roma "La Sapienza" miRNA biomarkers for the diagnosis of duchenne muscular dystrophy progression, for monitoring therapeutic interventions, and as therapeutics
WO2011078672A1 (en) 2009-12-24 2011-06-30 Prosensa Technologies B.V. Molecule for treating an inflammatory disorder
ES2683695T3 (es) 2010-01-12 2018-09-27 The University Of North Carolina At Chapel Hill Repeticiones terminales invertidas restrictivas para vectores virales
TWI541024B (zh) 2010-09-01 2016-07-11 日本新藥股份有限公司 反義核酸
WO2012109570A1 (en) 2011-02-10 2012-08-16 The University Of North Carolina At Chapel Hill Viral vectors with modified transduction profiles and methods of making and using the same
WO2012138846A2 (en) * 2011-04-05 2012-10-11 The Regents Of The University Of California Method and compositions comprising small rna agonist and antagonists to modulate inflammation
CN112251436A (zh) 2012-01-27 2021-01-22 比奥马林技术公司 治疗杜兴型肌营养不良症和贝克型肌营养不良症的具有改善特性的rna调节性寡核苷酸
US9636370B2 (en) 2012-09-28 2017-05-02 The University Of North Carolina At Chapel Hill AAV vectors targeted to oligodendrocytes
US9447433B2 (en) 2013-03-15 2016-09-20 The University Of North Carolina At Chapel Hill Synthetic adeno-associated virus inverted terminal repeats
JP6396988B2 (ja) 2013-03-15 2018-09-26 ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル 二重グリカン結合性ａａｖベクターのための方法および組成物
WO2016081811A1 (en) 2014-11-21 2016-05-26 The University Of North Carolina At Chapel Hill Aav vectors targeted to the central nervous system
AU2016206624B2 (en) 2015-01-14 2020-08-06 The University Of North Carolina At Chapel Hill Methods and compositions for targeted gene transfer
MX2017010698A (es) 2015-02-20 2018-04-30 Univ Texas Metodos y composiciones para chlamydia atenuada como vacuna y vector.
BR112018003665A2 (en) 2015-09-28 2018-09-25 The University Of North Carolina At Chapel Hill methods and compositions for antibody evasion viral vectors
EP4659816A3 (en) 2015-12-14 2025-12-31 The University of North Carolina at Chapel Hill MODIFIED CAPSID PROTEINS FOR IMPROVED PARVOVIRUS VECTOR DELIVERY
CN110770346B (zh) 2017-03-15 2024-01-12 北卡罗来纳-查佩尔山大学 多倍体腺相关病毒载体及其制备和使用方法
IL273245B2 (en) 2017-09-15 2025-03-01 Commw Scient Ind Res Org RNA molecules
BR112020016699A2 (pt) 2018-02-28 2020-12-15 The University Of North Carolina At Chapel Hill Métodos e composições para vetores de vírus de evasão de anticorpos
CA3094465A1 (en) 2018-04-03 2019-10-10 Stridebio, Inc. Virus vectors for targeting ophthalmic tissues
CN112543766A (zh) 2018-04-03 2021-03-23 斯特里迪比奥公司 抗体逃避性病毒载体
US20210363191A1 (en) 2018-04-03 2021-11-25 Stridebio, Inc. Antibody-evading virus vectors
CN112566923B (zh) 2018-06-12 2024-10-29 北卡罗来纳大学教堂山分校 合成嗜肝性腺相关病毒衣壳及其用途
EP3810782A2 (en) 2018-06-22 2021-04-28 Asklepios Biopharmaceutical, Inc. Vectors for gene delivery that persist within cells
BR112021018776A2 (pt) 2019-03-21 2021-11-30 Stridebio Inc Vetores de vírus adenoassociado recombinante
EP3959227A1 (en) 2019-04-26 2022-03-02 The University of North Carolina at Chapel Hill Methods and compositions for dual glycan binding aav2.5 vector
KR20220083714A (ko) 2019-10-17 2022-06-20 스트라이드바이오 인코포레이티드 니만-피크 질환 c형의 치료를 위한 아데노-연관 바이러스 벡터
EP4100523A4 (en) 2020-02-04 2024-03-06 Duke University COMPOSITIONS AND METHODS FOR CIRCULAR RNA EXPRESSION
US12209251B2 (en) 2020-05-05 2025-01-28 The University Of North Carolina At Chapel Hill Modified adeno-associated virus 5 capsids and uses thereof
EP4200408A1 (en) 2020-08-19 2023-06-28 Sarepta Therapeutics, Inc. Adeno-associated virus vectors for treatment of rett syndrome
ES3001131T3 (es) 2020-10-28 2025-03-04 Univ North Carolina Chapel Hill Métodos y composiciones para la unión dual de glicanos al vector de AAV2.5
WO2022093769A1 (en) 2020-10-28 2022-05-05 The University Of North Carolina At Chapel Hill Methods and compositions for dual glycan binding aav2.5 vector
TW202242124A (zh) 2021-01-14 2022-11-01 美商史崔德生物公司 靶向ｔ細胞之ａａｖ載體
US20240398993A1 (en) 2021-01-15 2024-12-05 Glenna FOIGHT Small molecule-regulated gene expression system
JP2024515626A (ja) 2021-04-16 2024-04-10 アスクレピオス バイオファーマシューティカル， インコーポレイテッド 血液脳関門を横断し低減された液性応答を惹起する合理的ポリプロイドａａｖビリオン
WO2023150687A1 (en) 2022-02-04 2023-08-10 Ginkgo Bioworks, Inc. Recombinant adeno-associated virus vectors, and methods of use thereof
JP2025507958A (ja) 2022-03-04 2025-03-21 ロックアネイビオ， インコーポレイテッド 操作された核内低分子ＲＮＡ（ｓｎＲＮＡ）を含む組成物および方法
AR128918A1 (es) * 2022-03-30 2024-06-26 Biomarin Pharm Inc Oligonucleótidos que omiten el exón 51 de distrofina y sus aplicaciones
CN120129747A (zh) * 2022-10-11 2025-06-10 广州瑞风生物科技有限公司 snRNA核酸分子及其应用
CN115806984B (zh) * 2022-10-18 2023-10-10 昆明理工大学 环状rna及载体和载体的应用
WO2024124019A2 (en) 2022-12-07 2024-06-13 Ginkgo Bioworks, Inc. Aav vectors targeting hematopoietic stem cells
WO2025079025A1 (en) 2023-10-13 2025-04-17 Takeda Pharmaceutical Company Limited Ides-rapamycin conjugate in aav gene therapy

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1191097A1 (en) * 2000-09-21 2002-03-27 Leids Universitair Medisch Centrum Induction of exon skipping in eukaryotic cells

Also Published As

Publication number Publication date
ATE449170T1 (de) 2009-12-15
PT1501931E (pt) 2010-02-23
SI1501931T1 (sl) 2010-03-31
EP2151497B1 (en) 2014-01-08
AU2003231928A8 (en) 2003-11-11
EP2151497A2 (en) 2010-02-10
CY1109746T1 (el) 2014-09-10
WO2003095647A2 (en) 2003-11-20
EP1501931B1 (en) 2009-11-18
WO2003095647A3 (en) 2004-02-19
DK1501931T3 (da) 2010-03-29
DE60330136D1 (de) 2009-12-31
ES2336909T3 (es) 2010-04-19
EP1501931A2 (en) 2005-02-02
AU2003231928A1 (en) 2003-11-11
ITRM20020253A0 (it) 2002-05-08
EP2151497A3 (en) 2010-03-10

Similar Documents

Publication Publication Date Title
ITRM20020253A1 (it) Molecole chimeriche di snrna con sequenze antisenso per le giunzioni di splicing del gene della distrofina e applicazioni terapeutiche.
ITRM20030149A1 (it) Oligonucleotidi (odn) antisenso per smad7 e loro usi in campo medico
CY1121139T1 (el) Επαγωγη παρακαμψης εξωνιου σε ευκαριωτικα κυτταρα
CY1116385T1 (el) Αντινοηματικη διαμορφωση της εκφρασης της απολιποπρωτεινης β
ATE531729T1 (de) Kdr-peptide und diese enthaltende impfstoffe
EA200000759A1 (ru) Производные 2-(пурин-9-ил)-тетрагидрофуран-3,4-диола
MXPA02012743A (es) Moleculas tipo il-17 y usos de las mismas.
DE60138715D1 (de) Tnf-rezeptor-ähnliche moleküle und deren anwendungen
EA200400812A1 (ru) Секретируемый белок
AP2000001999A0 (en) Gene therapy method.
EP1648910A4 (en) ANTISENSE MODULATION OF THE EXPRESSION OF STEAROYL COA DESATURASE
BR9902019A (pt) Moléculas de polinucleotìdios que codificam proteìnas de neospora.
ES2172801T3 (es) Procedimiento y dispositivo para la purificacion y enriquecimiento de moleculas.
ATE482976T1 (de) Defensinproteine
PL374550A1 (en) Il-17 like molecules and uses thereof
ATE556140T1 (de) Aav vektoren für die gentherapie von rheumatischer arthritis
ATE526400T1 (de) Metalloproteaseproteine
BR0003561A (pt) Processo para a preparação fermentativa de produtos metabólicos e para as sequências de nucleotìdeos codificando para o gene sod
HUP0100660A1 (hu) Negatív szabályozóelemek alkalmazása transzgének neurospecifikus kifejezésére
EA200501843A1 (ru) Tnf-подобный секретируемый белок
CY1114168T1 (el) Αντιπληροφοριακη διαμορφωση της εκφρασης της απολιποπρωτεϊνης β
GB0312210D0 (en) Amino acid sequences involved in endocytosis, nucleic acid sequences encoding such amino acid sequences, and use thereof in the field of cholesterol
AU2003215179A8 (en) Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and used thereof
MD2188F1 (en) Method of epilepsy treatment
TH87139A (th) การรักษาโรคโดยใช้ระบบการแสดงออกที่ควบคุมซึ่งปรับปรุงให้ดีขึ้น